Explore /
Poster
/ Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Authors

Leszek Kotula

Upstate Medical University, Syracuse, NY

Gennady Bratslavsky , Hugh A.G. Fisher , Timothy Byler , Robert John Corona , Joseph Jacob , Alina Basnet , Jon Chung , Julia Andrea Elvin , Jo-Anne Vergilio , James Suh , Shakti H. Ramkissoon , Sugganth Daniel , Eric Allan Severson , Alexa Betzig Schrock , Siraj Mahamed Ali , Vincent A. Miller , Laurie M. Gay , Jeffrey S. Ross , Leszek Kotula

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5061)

DOI

10.1200/JCO.2018.36.15_suppl.5061

Abstract #

5061

Poster Bd #

288

Abstract Disclosures

Similar Posters

Poster

2018 Genitourinary Cancers Symposium

$Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).$